Salix Pharmaceuticals, Ltd. announced that the US Patent and Trademark Office has issued three patents relating to rifaximin. US Patent No. 7,928,115 (the ‘115 patent), which issued April 19, 2011, provides protection to methods of treating Travelers' Diarrhoea (TD) with rifaximin. This patent should provide protection until July 24, 2029. This invention was a product of Salix's internal innovation and Salix is the assignee of all the rights and title to this patent. The ‘115 patent provides protection for the TD indication for the rifaximin 200mg product that the company markets in the United States under the trade name Xifaxan.

US Patent No. 7,906,542 (the ‘542 patent), which issued March 15, 2011, provides protection relating to pharmaceutical compositions comprising rifaximin in polymorphic forms. This patent should provide protection until June 1, 2025. Additionally, US Patent No. 7,902,206 (the ‘206 patent), which issued March 8, 2011 provides protection relating to rifaximin in polymorphic form alpha free from other polymorphic forms of rifaximin not derived from Form alpha by water absorption or release. This patent should provide protection until June 19, 2024.

Salix has an exclusive license to the ‘542 and ‘206 patents from Alfa Wassermann S.p.A. to use, sell, have sold and import licensed rifaximin products, which the company markets in the United States under the trade names Xifaxan (200mg) and Xifaxan 550 (550mg). The ‘542 and ‘206 patents provide protection for all indications currently marketed and being assessed.

Rifaximin is a gut–selective antibiotic with negligible systemic absorption and broad–spectrum activity in vitro against both gram–positive and gram–negative pathogens. Rifaximin has a similar tolerability profile to that of placebo.

Rifaximin tablets 200 mg is approved in over 30 countries worldwide. Alfa Wassermann S.p.A. in Bologna, Italy has marketed rifaximin in Italy under the trade name Normix for over 30 years. Salix acquired rights to market rifaximin in North America from Alfa Wassermann.